POEMS综合征的最佳一线治疗:自体移植、美法仑联合地塞米松还是来那度胺联合地塞米松?
该研究比较了347例POEMS综合征患者接受自体造血干细胞移植(ASCT,N=165)、美法仑联合地塞米松(MDex,N=79)或来那度胺联合地塞米松(LDex,N=103)一线治疗的缓解与生存。中位随访45个月,ASCT的血液学完全缓解(CRH)优于MDex,血管内皮生长因子完全缓解(CRV)优于MDex和LDex,但三组神经缓解无显著差异;ASCT的3年无进展生存(PFS)优于LDex,总生存(OS)三组无差异。中高危患者可能更多受益于ASCT。
要点
- ASCT的CRH为49.7%,优于MDex的37.7%(p=0.001)。
- ASCT的CRV为66.2%,优于MDex的38.5%(p=0.001)和LDex的47.7%(p=0.008)。
- ASCT的3年PFS为87.6%,优于LDex的64.9%(p=0.003)。
核心结论
- 三种一线治疗方案均有合理的缓解率和生存率,但高危患者可能更多受益于ASCT治疗。
研究设计与样本
- 研究比较了347例POEMS综合征患者接受三种一线治疗方案的缓解和生存,ASCT组165例,MDex组79例,LDex组103例。
主要发现
- 中位随访45个月,总体血液学完全缓解(CRH)为46.4%,血管内皮生长因子完全缓解(CRV)为55.1%,神经缓解(RN)为93.8%。
- ASCT的CRH为49.7%,优于MDex的37.7%(p=0.001)。
- ASCT的CRV为66.2%,优于MDex的38.5%(p=0.001)和LDex的47.7%(p=0.008)。
- 三种方案的RN分别为91.5%、100%和93.8%,差异无统计学意义(p=0.234)。
- 总体3年无进展生存(PFS)为80.5%,3年总生存(OS)为90.8%;ASCT的PFS为87.6%,优于LDex的64.9%(p=0.003);三种方案的OS无差异(p=0.079)。
关键数值与推荐
- 中高危患者中,ASCT的CRH和CRV优于MDex,PFS优于LDex。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
POEMS syndrome is a rare plasma cell dyscrasia. This study compared the responses to and survival of 347 POEMS syndrome patients given three first-line treatment regimens: autologous stem cell transplantation (ASCT, N = 165) and melphalan + dexamethasone (MDex, N = 79), or lenalidomide + dexamethasone (LDex, N = 103). After a median 45-month follow-up, overall hematologic complete remission (CRH) was 46.4%, vascular endothelial growth factor complete remission (CRV) was 55.1%, and neurological remission (RN) was 93.8%. CRH was better with ASCT (49.7%) than with MDex (37.7%, p = 0.001). CRV was better with ASCT (66.2%) than with MDex (38.5%, p = 0.001) or LDex (47.7%, p = 0.008). Differences in RN achieved by three regimens (91.5% vs. 100% vs. 93.8%, p = 0.234) were not significant. Overall 3-year progression-free survival (PFS) was 80.5% and overall 3-year overall survival (OS) was 90.8%. PFS was 87.6% with ASCT and 64.9% with LDex (p = 0.003). OS in the three regimens did not differ (p = 0.079). In medium-high risk patients, ASCT had better CRH and CRV than MDex, and better PFS than LDex. Therefore, although all three treatments had reasonable responses and survivals, patients with higher risk may benefit more from ASCT treatment.
引用
- Zhao H, Huang XF, Gao XM, et al. What is the best first-line treatment for POEMS syndrome: autologous transplantation, melphalan and dexamethasone, or lenalidomide and dexamethasone? Leukemia. 2019. PMID: 30700844. doi:10.1038/s41375-019-0391-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。